Cargando…

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy

INTRODUCTION: Current epidemiologic literature of rheumatologic immune-related adverse events (rh-irAEs) consists of clinical trials, case reports, or smaller, single-center series. We evaluate the occurrence of rh-irAEs during immune checkpoint inhibitor (ICI) therapy from US commercial claims data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anjohrin, Suzanne, Sheahan, Anna, Suruki, Robert, Stark, Jeffrey L., Sloan, Victor S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572292/ https://www.ncbi.nlm.nih.gov/pubmed/34491550 http://dx.doi.org/10.1007/s40744-021-00359-z

Ejemplares similares

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”
por: Sauder, Maxwell, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
por: Labadie, Brian W., et al.
Publicado: (2019)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
por: Moradian, Saeed, et al.
Publicado: (2023)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
por: Zhang, Dongyu, et al.
Publicado: (2021)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109
por: Zhang, Dongyu, et al.
Publicado: (2022)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes
por: Hao, Liping, et al.
Publicado: (2021)

Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
por: Dong, Liangbo, et al.
Publicado: (2023)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
por: Bai, Xue, et al.
Publicado: (2021)

Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
por: Leipe, Jan, et al.
Publicado: (2019)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
por: Shi, Congqi, et al.
Publicado: (2022)

Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy
por: Lusa, Amanda, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
por: Safi, Mohammed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2mdagnm87jllrl5sgmj8ubacit